Pesquisar
InMed Pharmaceuticals Inc
INMAdicionar à lista de desejos
1.560USD
-0.030-1.89%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
4.37MValor de mercado
PerdaP/L TTM
Mais detalhes de InMed Pharmaceuticals Inc Empresa
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
Informações de InMed Pharmaceuticals Inc
Código da empresaINM
Nome da EmpresaInMed Pharmaceuticals Inc
Data de listagemJun 21, 2001
CEOAdams (Eric A)
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 21
Endereço1445-885 West Georgia St.
CidadeVANCOUVER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalV6C 3E8
Telefone16046697207
Sitehttps://www.inmedpharma.com/
Código da empresaINM
Data de listagemJun 21, 2001
CEOAdams (Eric A)
Executivos da empresa InMed Pharmaceuticals Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
Ms. N. Netta (Neeta) Jagpal, CPA
Ms. N. Netta (Neeta) Jagpal, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Neil A. Klompas, CPA
Mr. Neil A. Klompas, CPA
Independent Director
Independent Director
--
--
Mr. John Bathery
Mr. John Bathery
Director
Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de InMed Pharmaceuticals Inc?
Os cinco principais acionistas de InMed Pharmaceuticals Inc são: Mr. Andrew Harold Hull
Quantas instituições possuem ações da InMed Pharmaceuticals Inc (INM)?
Em 2026Q1, 31 instituições possuíam ações da InMed Pharmaceuticals Inc, com valor de mercado aproximado de 320.11K, representando 9.66% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -43643.00.